Freedom Investment Management Inc. Makes New $243,000 Investment in BioNTech SE (NASDAQ:BNTX)

Freedom Investment Management Inc. acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,046 shares of the company’s stock, valued at approximately $243,000.

Other hedge funds have also recently modified their holdings of the company. Planning Capital Management Corp increased its holdings in shares of BioNTech by 45,000.0% in the third quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after purchasing an additional 450 shares during the last quarter. Blue Trust Inc. increased its stake in BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after acquiring an additional 388 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in shares of BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock worth $43,000 after acquiring an additional 252 shares in the last quarter. GAMMA Investing LLC boosted its position in shares of BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after acquiring an additional 238 shares during the last quarter. Finally, Clear Harbor Asset Management LLC purchased a new position in shares of BioNTech in the third quarter valued at $210,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Stock Performance

Shares of NASDAQ:BNTX opened at $118.39 on Monday. The firm’s 50 day simple moving average is $113.81 and its 200-day simple moving average is $98.73. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech SE has a one year low of $76.53 and a one year high of $131.49. The firm has a market cap of $28.38 billion, a PE ratio of -56.38 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, topping the consensus estimate of ($1.26) by $2.07. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company had revenue of $1.24 billion for the quarter, compared to the consensus estimate of $514.08 million. During the same period last year, the business posted $0.73 EPS. BioNTech’s quarterly revenue was up 38.9% on a year-over-year basis. As a group, equities analysts predict that BioNTech SE will post -3.72 EPS for the current year.

Analyst Upgrades and Downgrades

BNTX has been the subject of several research reports. TD Cowen lowered their price objective on shares of BioNTech from $132.00 to $122.00 and set a “hold” rating for the company in a research report on Tuesday, November 5th. Bank of America increased their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. Berenberg Bank began coverage on BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Finally, The Goldman Sachs Group raised BioNTech from a “neutral” rating to a “buy” rating and boosted their target price for the company from $90.00 to $137.00 in a research report on Friday, November 8th. Four equities research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, BioNTech has a consensus rating of “Moderate Buy” and an average target price of $138.67.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.